Imaging Biometrics, Ltd
(the “Company”)
Imaging Biometrics Announces Successful Completion of Phase 1 Trial of Gallium Maltolate in Recurrent Glioblastoma
Imaging Biometrics, LLC, (“IB”), a leader in advanced quantitative imaging solutions, today announces the successful completion of its Phase 1 clinical trial evaluating oral gallium maltolate (GaM) for the treatment of recurrent or relapsed glioblastoma (GBM) – a major milestone in the company’s oncology development program.
Following comprehensive internal reviews conducted by the Medical College of Wisconsin (MCW), the trial met all predefined Phase 1 objectives, including safety, tolerability, and pharmacokinetic benchmarks. Importantly, significant adverse events were not observed, underscoring GaM’s favorable safety profile.
“This achievement marks a pivotal step forward in our mission to bring novel, mechanism-driven therapies to patients with GBM,” said Trevor Brown, CEO of Imaging Biometrics Ltd. “We are encouraged by the data and the continued treatment of one long-standing patient, which speaks to GaM’s potential clinical benefit. We look forward to sharing the full summary analysis soon.”
The trial, led by Dr. Jennifer Connelly, MD (Principal Investigator) and Dr. Christopher Chitambar, MD (Co-Principal Investigator and Study Chair), enrolled 26 patients in a dose-escalation design. Of these, 24 were evaluable for toxicity, with 22 included in a preliminary efficacy assessment. All patients tolerated GaM exceptionally well, with no reported toxicities.
Oral GaM is a novel therapeutic candidate that targets tumor metabolism and iron-dependent cancer growth. Preclinical studies suggest its unique mechanism of action may synergize with existing treatment modalities, offering a promising new avenue for GBM therapy.
With Phase 1 now complete, IB is actively engaging with leading cancer centers to initiate a Phase 2 trial aimed at further evaluating GaM’s efficacy and expanding its clinical footprint.
–ENDS–
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
|
IB Ltd Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda Tel: 020 7469 0930 |
|
AlbR Capital Limited (Broker) Tel: 020 7220 9797 |
About Imaging Biometrics® LLC: IB is a wholly-owned subsidiary of Imaging Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com. Follow IB on X, @ImgBiometrics.